Hybridomas in Cancer Diagnosis and Treatment. Proceedings of a Workshop Held in Bethesda, Maryland, Sponsored by the Biological Response Modifier Program, Division of Cancer Treatment, National Cancer Institute. Progress in Cancer Research and Therapy, Volume 21. Malcolm S. Mitchell , Herbert F. Oettgen

1983 ◽  
Vol 58 (2) ◽  
pp. 308-309
Author(s):  
A. J. McMichael
Keyword(s):  
Cancer Research ◽  
Cancer Treatment ◽  
Cancer Diagnosis ◽  
National Cancer Institute ◽  
Biological Response ◽  
Biological Response Modifier ◽  
Diagnosis And Treatment ◽  
Response Modifier

Recent Advances of Silver Nanoparticles in Cancer Diagnosis and Treatment

2020 ◽  
Vol 20 (11) ◽  
pp. 1276-1287 ◽  
Author(s):  
Tran Q. Huy ◽  
Pham T.M. Huyen ◽  
Anh-Tuan Le ◽  
Matteo Tonezzer
Keyword(s):  
Silver Nanoparticles ◽  
Cancer Treatment ◽  
Cancer Diagnosis ◽  
Essential Role ◽  
Review Paper ◽  
Diagnosis And Treatment ◽  
Antimicrobial Material ◽  
Pathogenic Agents ◽  
New Generation ◽  
Carrier Systems

Background: Silver nanoparticles (AgNPs) are well-known as a promising antimicrobial material; they have been widely used in many commercial products against pathogenic agents. Despite a growing concern regarding the cytotoxicity, AgNPs still have attracted considerable interest worldwide to develop a new generation of diagnostic tool and effective treatment solution for cancer cells. Objective: This paper aims to review the advances of AgNPs applied for cancer diagnosis and treatment. Methods: The database has been collected, screened and analysed through up-to-date scientific articles published from 2007 to May 2019 in peer-reviewed international journals. Results: The findings of the database have been analysed and divided into three parts of the text that deal with AgNPs in cancer diagnosis, their cytotoxicity, and the role as carrier systems for cancer treatment. Thanks to their optical properties, high conductivity and small size, AgNPs have been demonstrated to play an essential role in enhancing signals and sensitivity in various biosensing platforms. Furthermore, AgNPs also can be used directly or developed as a drug delivery system for cancer treatment. Conclusion: The review paper will help readers understand more clearly and systematically the role and advances of AgNPs in cancer diagnosis and treatment.

scholarly journals Clinical Development of Biological Response Modifiers

1994 ◽  
Vol 5 (suppl a) ◽  
pp. 5A-8A
Author(s):  
Jay P Siegel
Keyword(s):  
Adverse Reactions ◽  
Biological Response ◽  
Clinical Trial Design ◽  
The United States ◽  
Biological Response Modifier ◽  
Clinical Development ◽  
Response Modifier ◽  
United States Food ◽  
Study Population ◽  
States Food

OBJECTIVE: To present perspectives on selected issues that frequently arise during the clinical development of biological response modifier (BRM) therapies.DATA SOURCES: The perspectives and opinions presented herein were developed over several years of reviewing and consulting on the clinical development of BRM therapies at the United States Food and Drug Administration.CONCLUSIONS: BRM therapies encompass a broad spectrum of products used to treat a wide variety of diseases. Due to this diversity. most principles of clinical trial design and conduct applicable to the majority of BRMS are those that are applicable to all therapies. Nevertheless, the clinical development of BRM therapies often raises specific issues and problems in the areas of selecting animal models, defining the study population, adverse reactions, dosing and defining end-points. Over 10 years’ experience in testing biotechnology derived BRMS in clinical trials has created a database from which we can draw valuable generalizations for guidance in future studies.

Inositol-C2-PAF acts as a biological response modifier and antagonizes cancer-relevant processes in mammary carcinoma cells

2018 ◽  
Vol 41 (5) ◽  
pp. 505-516 ◽  
Author(s):  
Carsten Pelz ◽  
Sonja Häckel ◽  
Geo Semini ◽  
Sandra Schrötter ◽  
Willem Bintig ◽  
...  
Keyword(s):  
Mammary Carcinoma ◽  
Biological Response ◽  
Biological Response Modifier ◽  
Carcinoma Cells ◽  
Response Modifier ◽  
Mammary Carcinoma Cells
Sign in / Sign up

Export Citation Format

Share Document